Mary Grecco

DocwireNews

SCLC is a rapidly progressing cancer that initially responds to first-line therapy but almost always relapses, and prognosis for these patients is poor due to limited second-line treatment options. Tarlatamab is a bispecific T-cell engager molecule that engages both CD3 on T cells and delta-like ligand 3 on SCLC cells, leading to T-cell-mediated lysis of SCLC cells.
Previous results from the phase 1 DeLLphi-300 study of tarlatamab in patients with heavily pretreated relapsed or refractory SCLC showed a manageable safety profile, along with antitumor activity and an encouraging response durability. This trial was followed by the phase 2, open-label DeLLphi-301 study that evaluated patients with advanced SCLC treated with a platinum-based regimen and one other line of therapy. Results from DeLLphi-301 and updated details of the phase 3 trial in progress were presented at the 2023 North America Conference on Lung Cancer.
Results from the phase 2 study showed that tarlatamab at a dose of 10 mg every 2 weeks demonstrated anticancer activity, with an overall response rate of 40% and a manageable safety profile in patients with previously treated SCLC. DeLLphi-304 is a global, open-label, randomized phase 3 trial that will evaluate the efficacy and safety of tarlatamab against SOC in approximately 700 patients with relapsed SCLC following platinum-based first-line chemotherapy, with a goal of providing clarity on long-term response durability and survival benefits.
Patients are randomized 1:1 to receive tarlatamab or SOC (lurbinectedin or topotecan or amrubicin per local SOC), stratified by prior anti-PD-L1 treatment, chemotherapy-free interval, presence of brain metastases, and SOC (topotecan/amrubicin vs lurbinectedin). The primary objective is to compare the efficacy of tarlatamab with SOC in prolonging OS. Key secondary end points include comparison of PFS and patient-reported outcomes. Eligibility criteria include adults with histologically or cytologically confirmed relapsed SCLC who progressed following one platinum-based regimen, along with measurable lesions per Response Evaluation Criteria in Solid Tumors 1.1 and adequate organ function. Enrollment is currently ongoing (NCT05060016).
Source: Paz-Ares L, Felip E, Ahn M-J, et al. Trial in progress: randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in relapsed small cell lung cancer (DeLLphi-304). Abstract of a poster presented at the 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, Illinois.

Cecilia Brown

Phase 3 MARIPOSA Study Meets OS Endpoint in EGFR-Positive NSCLC

EGFR+ NSCLC

Laura Litwin

Multiple Studies Highlight Wide Spectrum of Cardiovascular Benefits Provided by Anti-Obesity Drugs

Preventive Cardiology

Adding Amivantamab to Chemotherapy Shows OS Benefit for Certain Patients With NSCLC

Latest News

Comparing the Standard of Care With Tarlatamab in Relapsed Small Cell Lung Cancer: DeLLphi-304

Small Cell Lung Cancer

The DeLLphi-301 study that evaluated patients with advanced SCLC.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe